This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Colony stimulating factor 1 receptor (CSF1R; C-FMS; CD115)	<p>A study in mice suggests that inhibiting CSF1R could help treat cancer. In a mouse model of prostate cancer, a CSF1R inhibitor reduced infiltration of myeloid-derived suppressor cells compared with vehicle ($p < 0.01$). Myeloid-derived suppressors are associated with tumor angiogenesis and resistance to angiogenesis inhibitors. In a mouse model of lung cancer, treatment with the CSF1R inhibitor, as compared to vehicle, increased the efficacy of antiangiogenic therapy ($p < 0.0001$). Next steps include evaluating the combination of CSF1R inhibition and angiogenesis inhibitors in other animal models of cancer.</p> <p>SciBX 3(2); doi:10.1038/scibx.2010.41 Published online Jan. 14, 2010</p>	Two patents pending covering pharmacologic blockade of CSF1R signaling in solid cancers, atherosclerosis and inflammatory diseases; licensing status undisclosed	<p>Priceman, S.J. <i>et al. Blood</i>; published online Dec. 11, 2009; doi:10.1182/blood-2009-08-237412 Contact: Lily Wu, University of California, Los Angeles, Calif. e-mail: lwu@mednet.ucla.edu</p>